Company: MIRA
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001183
Chunk: 1119

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 9B
Chunk 1119
---
  
     -  
     148,703 
  
    Stock-based
    compensation 
     -  
     -  
     1,920,805  
     -  
     1,920,805 
  
    Net
    loss 
     -  
     -  
     -  
     (7,852,659) 
     (7,852,659)
  
    Balances,
    December 31, 2024 
    $16,560,852  
    $1,656  
    $31,335,815  
    $(29,137,721) 
    $2,199,750 
  
    Balance 
    $16,560,852  
    $1,656  
    $31,335,815  
    $(29,137,721) 
    $2,199,750 

See
notes to consolidated financial statements

F-6

MIRA
PHARMACEUTICALS, INC.

STATEMENTS
OF CASH FLOWS

    2024  
    2023 

    Year
    Ended December 31, 

    2024  
    2023 
  
    Cash
    flows from operating activities 

    Net
    loss 
    $(7,852,659) 
    $(11,982,343)
  
    Adjustments
    to reconcile net loss to net cash from operations 

    Non-cash
    interest expense 
     -  
     3,456,294 
  
    Stock-based
    compensation expense 
     1,920,805  
     2,550,946 
  
    Non-cash warrant expense 
     -  
     1,832,388 
  
    Non-cash
    investor relations fees 
     -  
     250,000 
  
    Change
    in operating assets and liabilities: 

    Right
    of use lease, net 
     -  
     5,500 
  
    Prepaid
    expenses 
     189,073  
     (243,802)
  
    Other
    receivables 
     11,862  
     (11,862)
  
    Trade
    accounts payable and accrued expenses 
     184,785  
     (389,524)